Filter by content type
Filter by content year
Filter by form group
Filter by type
Filter by tags
Filter by gallery
Filter by category
Filter by category
Filter by category
Filter by category
Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy
December 13, 2019 - … gosuranemab; the potential of our commercial business and pipeline programs, including gosuranemab; and risks and … gosuranemab; the potential of our commercial business and pipeline programs, including gosuranemab; and risks and … gosuranemab; the potential of our commercial business and pipeline programs, including gosuranemab; and risks and …
Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE)
December 3, 2019 - … for BIIB059; the potential of our commercial business and pipeline programs, including BIIB059; data readouts and … for BIIB059; the potential of our commercial business and pipeline programs, including BIIB059; data readouts and … for BIIB059; the potential of our commercial business and pipeline programs, including BIIB059; data readouts and …
Biogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study for an Inherited Retinal Disorder
November 21, 2019 - … of CHM; the potential of our commercial business and pipeline programs, including timrepigene emparvovec; and … of CHM; the potential of our commercial business and pipeline programs, including timrepigene emparvovec; and … of CHM; the potential of our commercial business and pipeline programs, including timrepigene emparvovec; and …
Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis
November 6, 2019 - … company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of … SB15; the potential of Biogen’s commercial business and pipeline programs, including BENEPALI, FLIXABI, IMRALDI, SB11 … company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of …
Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis
October 30, 2019 - … commercial product portfolio and a substantial clinical pipeline of product candidates for diseases that include … of MS; the potential of Biogen’s commercial business and pipeline programs, including VUMERITY and TECFIDERA; the … commercial product portfolio and a substantial clinical pipeline of product candidates for diseases that include …
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
October 22, 2019 - … of AD; the potential of Biogen’s commercial business and pipeline programs, including aducanumab; the anticipated … of AD; the potential of Biogen’s commercial business and pipeline programs, including aducanumab; the anticipated … of AD; the potential of Biogen’s commercial business and pipeline programs, including aducanumab; the anticipated …
Biogen and Samsung Bioepis to Present Data for Infliximab and Adalimumab Biosimilars at United European Gastroenterology Week
October 21, 2019 - … Hall 7] “We remain committed to advancing our strong pipeline of biosimilar candidates, so that more patients and … company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of … Hall 7] “We remain committed to advancing our strong pipeline of biosimilar candidates, so that more patients and …
Biogen Announces Leadership Update
October 1, 2019 - … contributions and for the substantial progress made in our pipeline during his three years at Biogen. He has … scientist, I will continue to be focused on advancing our pipeline with the goal of pioneering new scientific … to realize the full potential of a significantly expanded pipeline. I believe it is the right time to pass the baton, …
Eisai And Biogen To Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease
September 13, 2019 - … Eisai ; the potential of Biogen's commercial business and pipeline programs, including BAN2401; the timing and scope of … Eisai ; the potential of Biogen's commercial business and pipeline programs, including BAN2401; the timing and scope of … Eisai ; the potential of Biogen's commercial business and pipeline programs, including BAN2401; the timing and scope of …
New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA® (dimethyl fumarate) Over 10 Years
September 11, 2019 - … and plans; the potential of our commercial business and pipeline programs, including diroximel fumarate; the … and plans; the potential of our commercial business and pipeline programs, including diroximel fumarate; the … and plans; the potential of our commercial business and pipeline programs, including diroximel fumarate; the …
